Evidence map›Paper›PMID 39737858›Full record

ArticleHead & neck2025

On TRacK With Larotrectinib in a Neonate With a Giant Congenital ETV6::NTRK3 Fusion-Positive Infantile Fibrosarcoma of the Head and Neck.

Teresa M Cardesa-Salzmann, Monika Sparber-Sauer, Peter Hingst, Andreas Erbersdobler, Bjoern Schneider, Maja Hühns, Andre Jakob, Friederike Terpe, Christian Spang, Dorothea Stalmann and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Teresa M Cardesa-SalzmannDepartment of Pediatric Hematology & Oncology, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.ORCID 0000-0003-2142-6898
Monika Sparber-SauerDepartment of Pediatric Hematology & Oncology, Zentrum für Kinder Und Jugendmedizin, Klinikum Stuttgart- Olgaspital, Stuttgart Cancer Center, Stuttgart, Germany.
Peter HingstDepartment of Pediatric Hematology & Oncology, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Andreas ErbersdoblerDepartment of Pathology, Universitätsmedizin Rostock, Rostock, Germany.
Bjoern SchneiderDepartment of Pathology, Molecular Pathology, Universitätsmedizin Rostock, Rostock, Germany.ORCID 0000-0002-0282-7330
Maja HühnsDepartment of Pathology, Molecular Pathology, Universitätsmedizin Rostock, Rostock, Germany.
Andre JakobDepartment of Pediatric Intensive Care Unit, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Friederike TerpeDepartment of Pediatric Intensive Care Unit, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Christian SpangDepartment of Pediatric Intensive Care Unit, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Dorothea StalmannDepartment of Pediatrics, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Claudia BierwirthDepartment of Pediatric Radiology, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Christina HauensteinDepartment of Pediatric Radiology, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Stefanie MärzheuserDepartment of Pediatric Surgery, Klinik Und Poliklinik für Kinderchirurgie, Universitätsmedizin Rostock, Rostock, Germany.
Manfred BallmannDepartment of Pediatrics, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.
Carl Friedrich ClassenDepartment of Pediatric Hematology & Oncology, Klinik für Kinder- Und Jugendmedizin, Universitätsmedizin Rostock, Rostock, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence in the head and neck region is rare. Complete non-mutilating surgical resection is often not possible, requiring multimodal treatment. IFS frequently harbors neurotrophic receptor tyrosine kinase (NTRK) fusions. Targeted therapy with NTRK inhibitors is modifying treatment paradigms of IFS.

methodsHerein, we report the case of a neonate with a giant unresectable congenital ETV6::NTRK3 (+) IFS of the head and neck region without rapid response to chemotherapy who was treated with larotrectinib oral suspension.

resultsLarotrectinib was well tolerated and induced an impressive clinical and radiologic response.

conclusionsThis case illustrates an example of pediatric precision oncology in a neonate with an ETV6::NTRK3 (+) congenital IFS of the head and neck region and provides further reference for the use of larotrectinib in the neonatal period.

Indexed as

FibrosarcomaHead and Neck NeoplasmsProto-Oncogene Proteins c-etsPyrazolesPyrimidinesRepressor ProteinsAntineoplastic AgentsETS Translocation Variant 6 ProteinHumansInfant, NewbornOncogene Proteins, FusionReceptor, trkCAntineoplastic AgentsETS Translocation Variant 6 ProteinETV6-NTRK3 fusion protein, humanlarotrectinibOncogene Proteins, FusionProto-Oncogene Proteins c-etsPyrazolesPyrimidinesReceptor, trkCRepressor ProteinsETV6::NTRK3infantile fibrosarcomaneonatepediatric precision oncologytargeted therapy with larotrectinib

Identifiers

PMID39737858
PMCPMC12038221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.